| Dr Shirley J Welden, MD | |
|
1921 Stonecipher Blvd, Ada, OK 74820 | |
| (580) 421-4570 | |
| Not Available |
| Full Name | Dr Shirley J Welden |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 40 Years |
| Location | 1921 Stonecipher Blvd, Ada, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114123619 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 15236 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chickasaw Nation Medical Center | Ada, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chickasaw Nation Division Of Health | 8426957523 | 209 |
News Archive
A randomized trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.
New Zealand company Promisia Integrative Limited, announced today significant positive results from a clinical trial on their natural dietary supplement Arthrem. The results have been published in the December 2015 issue of Clinical Rheumatology, a prestigious international peer reviewed medical journal.
Despite a national opioid-related overdose epidemic that continues to claim tens of thousands of lives annually, a new nationwide study shows that a scant proportion of hospitalized patients with opioid use disorder receive proven life-saving medications both during and after they're discharged.
According to a new study elevated levels of a molecule called RBP4 (retinol binding protein 4) forecast the early stages of the development of insulin resistance, a major cause of type 2 diabetes as well as cardiovascular disease and metabolic syndrome.
› Verified 7 days ago
| Entity Name | Chickasaw Nation Division Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255364923 PECOS PAC ID: 8426957523 Enrollment ID: O20040108000364 |
News Archive
A randomized trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.
New Zealand company Promisia Integrative Limited, announced today significant positive results from a clinical trial on their natural dietary supplement Arthrem. The results have been published in the December 2015 issue of Clinical Rheumatology, a prestigious international peer reviewed medical journal.
Despite a national opioid-related overdose epidemic that continues to claim tens of thousands of lives annually, a new nationwide study shows that a scant proportion of hospitalized patients with opioid use disorder receive proven life-saving medications both during and after they're discharged.
According to a new study elevated levels of a molecule called RBP4 (retinol binding protein 4) forecast the early stages of the development of insulin resistance, a major cause of type 2 diabetes as well as cardiovascular disease and metabolic syndrome.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shirley J Welden, MD 1921 Stonecipher Blvd, Ada, OK 74820 Ph: (580) 421-4570 | Dr Shirley J Welden, MD 1921 Stonecipher Blvd, Ada, OK 74820 Ph: (580) 421-4570 |
News Archive
A randomized trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.
New Zealand company Promisia Integrative Limited, announced today significant positive results from a clinical trial on their natural dietary supplement Arthrem. The results have been published in the December 2015 issue of Clinical Rheumatology, a prestigious international peer reviewed medical journal.
Despite a national opioid-related overdose epidemic that continues to claim tens of thousands of lives annually, a new nationwide study shows that a scant proportion of hospitalized patients with opioid use disorder receive proven life-saving medications both during and after they're discharged.
According to a new study elevated levels of a molecule called RBP4 (retinol binding protein 4) forecast the early stages of the development of insulin resistance, a major cause of type 2 diabetes as well as cardiovascular disease and metabolic syndrome.
› Verified 7 days ago
Gary L Paddack, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 902 Arlington Ctr, Pmb 224, Ada, OK 74820 Phone: 580-436-2262 Fax: 580-272-0186 | |
Dr. Shrina Parekh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-301-6465 | |
Elizabeth Omojasola Omoniyi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 N Monte Vista St Ste A, Ada, OK 74820 Phone: 580-453-3545 Fax: 580-453-3546 | |
Steven Louis Fillmore, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Dr. Quyen Thanh Ha, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 430 N Monte Vista St, Valley View Reg Hospital Wound Care Center, Ada, OK 74820 Phone: 580-272-1731 Fax: 580-272-1720 | |
Jerry S Morgan, M D L L C Internal Medicine Medicare: Medicare Enrolled Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-436-3980 Fax: 580-272-2708 |